IBSA USA Announces FDA Approval of VYBRIQUE™, the First and Only Oral Film to Treat Men with Erectile Dysfunction
IBSA USA, the U.S. subsidiary of the Swiss pharmaceutical company IBSA, announced today that the Food and Drug Administration (FDA) has approved VYBRIQUE™, the first sildenafil oral film available to treat men aged 18 years and older with erectile dysfunction.
Two Young Researchers from US Institutions among the Six Winners of the 12th Edition of the Fellowships Promoted by IBSA Foundation for Scientific Research
Research means investing in the future. This is the guiding principle behind the IBSA Foundation Fellowships program, which for over a decade, has supported talented young researchers from universities and research institutions around the world. The program awards grants to promote innovative and potentially groundbreaking projects in lesser-explored scientific fields; and has been a constantly growing success, as demonstrated by the 259 applications received for the 2024 edition, which marked a new record, across five therapeutic areas.
IBSA celebrates 40 years of history: “Drugs in the best form” – a success story that combines innovation with a focus on people
The year 2025 marks an important year for the IBSA Group (Institut Biochimique SA), which celebrates a double anniversary: 40 years of leadership by its CEO and President Arturo Licenziati, and 80 years since the creation of the IBSA name. These milestones coincide with another significant event: the 90th birthday of President Licenziati, who today – April 3, 2025 – celebrates this major occasion.
IBSA USA Expands Its IBSA Care Line of Dietary Supplements With Irosolv™
IBSA USA today announced the launch of Irosolv™ (Iron 30 mg & Folic Acid 400 mcg oral film strip), the newest addition to its IBSA Care line of dietary supplements. This expansion highlights IBSA’s dedication to providing carefully selected dietary supplements that leverage novel technology for improved tolerability and user convenience.
IBSA USA Expands Its IBSA Care Line With the Introduction of Three New Dietary Supplements
IBSA USA announced the addition of three new products to its IBSA Care line of dietary supplements: Ioselen™, FilmTec™ D3, and FilmTec™ B12. These offerings showcase IBSA’s commitment to enhancing health through select dietary supplements that utilize novel technology for absorption, tolerability, and user convenience. Earlier this year, the company launched Syrel™ (selenium + BioPerine®) and Thirodium™ (iodine), the first two products in the IBSA Care line.
Professional Pickleball Player James Ignatowich Partners With IBSA USA to Promote Licart®
Professional Pickleball Association (PPA Tour) player James Ignatowich has partnered with IBSA USA to promote Licart® (diclofenac epolamine) topical system 1.3%. Licart is the only once-a-day topical nonsteroidal anti-inflammatory (NSAID) patch approved by the U.S. Food and Drug Administration (FDA) to treat acute pain due to minor strains, sprains, and contusions.1
IBSA USA Renews Partnership With Professional Golfer Aza Muñoz to Promote Tirosint®-SOL
IBSA USA has renewed its partnership with professional golfer Azahara (Aza) Muñoz to promote Tirosint®-SOL (levothyroxine sodium) oral solution, a unique liquid hypothyroidism treatment, through the 2025 golf season. As part of the multi-year renewal, Muñoz will continue to serve as a spokesperson at in-person events, in videos, and on social media to promote the brand while wearing the Tirosint-SOL logo on the sleeve of her golf attire.
IBSA Introduces Two New Dietary Supplements Into the U.S. Market
IBSA USA announced that its Syrel™ (selenium + BioPerine®) and Thirodium™ (iodine) brands are now available in the U.S. Manufactured and marketed by IBSA, Syrel and Thirodium are select dietary supplements that contain two vital micronutrients for thyroid support – selenium and iodine respectively. These new dietary supplements are the first two of the company’s line of IBSA Care products.
